Bone marrow microvessel density is a prognostic factor for survival in patients with multiple myeloma. - Wikidata - awgldk - TriplyDB

Bone marrow microvessel density is a prognostic factor for survival in patients with multiple myeloma.

Bone marrow microvessel density is a prognostic factor for survival in patients with multiple myeloma.

http://www.wikidata.org/entity/Q52967907

about

Phase II open label study of the oral vascular endothelial growth factor-receptor inhibitor PTK787/ZK222584 (vatalanib) in adult patients with refractory or relapsed diffuse large B-cell lymphoma Vascular endothelial growth factor-related pathways in hemato-lymphoid malignancies.Vascular endothelial growth factor and its receptors in multiple myeloma.Multifunctional role of matrix metalloproteinases in multiple myeloma: a study in the 5T2MM mouse model.Bone marrow angiogenesis and progression in multiple myeloma: clinical significance and therapeutic approach.Proliferation, apoptosis, and intratumoral vascularity in multiple myeloma: correlation with the clinical stage and cytological grade.The relation between bone marrow angiogenesis and the proliferation index Ki-67 in multiple myeloma.Adverse prognostic impact of bone marrow microvessel density in multiple myeloma Bone marrow angiogenesis in multiple myeloma.Current and future imaging modalities for multiple myeloma and its precursor states.Plasma Levels of Monocyte Chemotactic Protein-1 Are Associated with Clinical Features and Angiogenesis in Patients with Multiple Myeloma.Thalidomide in multiple myeloma: past, present and future.Murine 5T multiple myeloma cells induce angiogenesis in vitro and in vivo.Targeting the vascular endothelial growth factor pathway in the treatment of multiple myeloma.Whole body MRI and PET/CT in haematological malignancies.Novel anti-myeloma agents and angiogenesis.Angiogenic cytokines profile in smoldering multiple myeloma: no difference compared to MGUS but altered compared to symptomatic myeloma.BAFF and APRIL as TNF superfamily molecules and angiogenesis parallel progression of human multiple myeloma.Clinical trials with anti-angiogenic agents in hematological malignancies.Biological aspects of angiogenesis in multiple myeloma.Whole-body MRI, dynamic contrast-enhanced MRI, and diffusion-weighted imaging for the staging of multiple myeloma.The selective adhesion molecule inhibitor Natalizumab decreases multiple myeloma cell growth in the bone marrow microenvironment: therapeutic implications.Phenylhexyl isothiocyanate has dual function as histone deacetylase inhibitor and hypomethylating agent and can inhibit myeloma cell growth by targeting critical pathways.Angiogenesis and multiple myeloma.Soluble Fms-like tyrosine kinase-1 expression inhibits the growth of multiple myeloma in nude mice.Prognostic value of bone marrow microvessel density and angiogenic cytokines in patients with multiple myeloma undergoing autologous stem cell transplant.Effect of thalidomide therapy on bone marrow angiogenesis in multiple myeloma.The significance of non correlation between interleukin-8 serum levels with bone marrow microvascular density in patients with myeloma multiple.Micro-vessel density and the expression of vascular endothelial growth factor (VEGF) and platelet-derived endothelial cell growth factor (PdEGF) in classical Hodgkin lymphoma (HL).Pro-inflammatory State in Monoclonal Gammopathy of Undetermined Significance and in Multiple Myeloma Is Characterized by Low Sialylation of Pathogen-Specific and Other Monoclonal Immunoglobulins.VEGF, ANGPT1, ANGPT2, and MMP-9 expression in the autologous hematopoietic stem cell transplantation and its impact on the time to engraftment.Prognostic value of bone marrow angiogenesis in patients with multiple myeloma undergoing high-dose therapy.Expression of C-Reactive Protein in Rectal Cancer.Microvessel Density as a Surrogate Prognostic Marker in Patients with Multiple Myeloma: A Meta-Analysis.Decrease of bone marrow angiogenesis in myeloma patients achieving a remission after chemotherapy.Circulating angiopoietin-1 to angiopoietin-2 ratio is an independent prognostic factor for survival in newly diagnosed patients with multiple myeloma who received therapy with novel antimyeloma agents.A Phase II trial of pegylated liposomal doxorubicin, vincristine, and reduced-dose dexamethasone combination therapy in newly diagnosed multiple myeloma patients.Expression of VEGF and its receptors by myeloma cells Bone marrow angiogenesis in multiple myeloma: effect of therapy Prognostic value of hepatocyte growth factor, syndecan-1, and osteopontin in multiple myeloma and monoclonal gammopathy of undetermined significance

P2860

Q33406444-23E70278-9291-4B28-848E-D4E92002037E Q33874179-0D61C730-E979-48C1-9B9A-5219E0905EBD Q34265556-FE515D1A-0363-4DA7-B784-FCBCCE78000B Q35103092-3288FF75-DD81-4191-ACC0-81526D34E2E5 Q35175287-55F826C4-DB32-4709-ADDA-4AA216FE05B6 Q35586240-F7F53DEE-56B8-4ECA-BA90-255F0A99B664 Q35587856-C99B1421-9EE1-4B66-92D5-2DF779A69B0A Q36083670-936EBD73-C66F-4A42-B208-994E381ACBAC Q36343529-207BF9AF-D196-499E-8CF4-DD632A59CAF6 Q36457735-3C9D5711-ED87-49F6-95C0-B91E2DF07D86 Q36564495-343AF492-C2B9-4996-B0C8-76F2D8909CBD Q36616493-CEAA4BAC-22A7-49BE-AD59-A35BCA40DF94 Q36644266-01FDE14F-098A-42CE-82E5-69146D231D4C Q36788503-CB59FBF7-2830-4E29-AA13-FC19126A6C93 Q36963742-1D48F695-04F1-4C2F-8243-5D09DEF23118 Q37132903-A2AE59BA-1602-4A2E-89F3-0F426A4E08E9 Q37413352-E724D654-E31F-4E16-8532-E3EDBC6109BB Q37622417-74D6F8A1-D345-4614-A295-1EA2B2F55981 Q37766940-4144F35B-FD68-42ED-BCEF-746F880B71F1 Q37956524-9FC41C61-28BF-40CA-9381-3A609B1C86B2 Q39176990-391357BA-FE77-4830-9E4E-21CDEBD0BE86 Q39472801-14CB4C01-8D3B-4477-8E2B-7DD850A0B231 Q39523561-25D91CF0-885B-4631-A28E-7CDD381AAE83 Q39696428-8A4CDB7E-4F74-4AF7-ABB0-8F8D3C82EE8B Q40109080-17C332A8-08D2-4391-AFAF-A41F602A8AF4 Q44611862-7CB285B3-0D98-4A2B-B514-9D3F2AB6DF87 Q44746790-984C3156-D1E4-4F59-817D-07EEF39376CF Q46554858-2F4E03EB-2E60-4551-8DB7-645364882694 Q46830786-9D8B0305-7B7B-4EC5-AF30-67E541B08780 Q47132349-F650FA47-B8B3-43C6-A374-AB1FC6B5F0FF Q47733010-A9EB70D1-9E38-45CF-8FF0-2CD196A6AD84 Q49286760-4475D0E4-321B-4103-A306-9CB3D2E1B94D Q50233617-7C77508E-4656-496F-A6C0-78156FB4F1F5 Q51810088-58877AE7-1C27-4106-93FA-CEA0E6700BA0 Q52964187-3CC9F86C-208E-403D-808F-8388DAC2B579 Q53155413-96AEE534-25B6-42E1-BA0B-BEF4C48FCCE8 Q53951659-0FAF8829-3892-433D-B644-646B2F51F0B2 Q58050891-E5BFF378-988E-4644-AB0E-8DA55844C5D2 Q58050905-5A0ED246-B744-424F-B153-02B3E3FF8528 Q58914769-165AA7B7-4216-4EC3-ACE7-89B99B83D5A0

P2860

Bone marrow microvessel density is a prognostic factor for survival in patients with multiple myeloma.

http://www.wikidata.org/entity/Q52967907

description

2000 nî lūn-bûn

@nan

2000年の論文

@ja

2000年学术文章

@wuu

2000年学术文章

@zh

2000年学术文章

@zh-cn

2000年学术文章

@zh-hans

2000年学术文章

@zh-my

2000年学术文章

@zh-sg

2000年學術文章

@yue

2000年學術文章

@zh-hant

name

Bone marrow microvessel densit ...... atients with multiple myeloma.

@en

Bone marrow microvessel densit ...... atients with multiple myeloma.

@nl

type

label

Bone marrow microvessel densit ...... atients with multiple myeloma.

@en

Bone marrow microvessel densit ...... atients with multiple myeloma.

@nl

prefLabel

Bone marrow microvessel densit ...... atients with multiple myeloma.

@en

Bone marrow microvessel densit ...... atients with multiple myeloma.

@nl

P1433

Q52967907-CEE4F345-95E4-48B5-9F55-E9FB40309BF4

P1476

Q52967907-F53FB685-524E-4FFD-9323-406B653CB840

P2093

Q52967907-25F4658D-6247-4336-8F44-893CE8D7022A

Q52967907-74571062-43CF-4534-A0B6-2EF9960FEC41

Q52967907-8AD654E4-C0BA-4C94-934A-3821090A560F

Q52967907-A38B771C-D2AA-4DA7-8287-B037F8525365

Q52967907-B537EE6D-C4EB-4CBF-8F45-969A6ABC6110

Q52967907-BF91879A-5AAF-4E5A-8B28-B94C9D378234

Q52967907-C58D71A8-1DD4-409A-A726-045A08A79539

Q52967907-E91FDA6E-67A4-4A59-9CC7-AA1427273376

P304

Q52967907-EDCB284F-FA6F-4933-9BAD-E8A9E912CB37

P31

Q52967907-5EDC6006-358E-4370-BF9F-CDB85ADB838B

P356

Q52967907-AE59058D-4D2F-4D48-8F4E-F57832A57F11

P433

Q52967907-68837E3B-6D60-432D-88D1-5C7C442C9AC7

P478

Q52967907-014B7985-97FA-4972-B3C6-FA6A5F646E42

P577

Q52967907-F31A8BC2-D49C-497F-8FFB-5FD88E55743C

P698

Q52967907-EBE06A39-1CE7-4BF0-B789-8BB3BE858F35

P921

Q52967907-48A072C0-CE6C-403D-97F3-71BB94860B1B

P356

P1433

Annals of Hematology

P1476

Bone marrow microvessel densit ...... atients with multiple myeloma.

@en

P2093

Dietel M

http://www.w3.org/2001/XMLSchema#string

Eucker J

http://www.w3.org/2001/XMLSchema#string

Jakob C

http://www.w3.org/2001/XMLSchema#string

Kaufmann O

http://www.w3.org/2001/XMLSchema#string

Niemöller K

http://www.w3.org/2001/XMLSchema#string

Possinger K

http://www.w3.org/2001/XMLSchema#string

Sezer O

http://www.w3.org/2001/XMLSchema#string

Zavrski I

http://www.w3.org/2001/XMLSchema#string

P304

574-577

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S002770000236

http://www.w3.org/2001/XMLSchema#string

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

79

http://www.w3.org/2001/XMLSchema#string

P577

2000-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

11100749

http://www.w3.org/2001/XMLSchema#string

P921